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BACKGROUND: Renin-angiotensin-aldosterone system
(RAAS) inhibitors are associated with hyperkalemia, but
there is little evidence demonstrating patients who
receive potassium monitoring have a lower rate of
hyperkalemia.
OBJECTIVE: To evaluate the association between po-
tassium monitoring and serious hyperkalemia-associ-
ated adverse outcomes among patients with diabetes
newly initiating RAAS inhibitor therapy.
DESIGN: Retrospective observational study.
PARTICIPANTS: Patients with diabetes without end-
stage renal disease initiating RAAS inhibitor therapy
between 2001 and 2006 at three integrated health care
systems.
MEASUREMENTS: Potassium monitoring and first
hyperkalemia-associated adverse event during the ini-
tial year of therapy. Hyperkalemia-associated adverse
events included hospitalizations, emergency depart-
ment visits or deaths within 24 h of hyperkalemia
diagnosis and/or diagnostic potassium ≥6 mmol/l.
Incidence rates were calculated in person-years (p-y).
We used inverse probability propensity score weighting
to adjust for differences between patients with and
without monitoring; Poisson regression was used to
obtain adjusted relative risks.
RESULTS: A total of 19,391 of 27,355 patients (71%)
received potassium monitoring. Serious hyperkalemia-
associated events occurred at an incidence rate of 10.2
per 1,000 p-y. Compared to patients without monitor-
ing, adjusted relative risk of hyperkalemia-associated
adverse events among all patients with monitoring was
0.50 (0.37, 0.66); in the subset of patients who also had
chronic kidney disease (n=2,176), adjusted relative risk
was 0.29 (0.18, 0.46).
CONCLUSIONS: Patients prescribed RAAS inhibitors
who have both diabetes and chronic kidney disease and
receive potassium monitoring are less likely to experi-
ence a serious hyperkalemia-associated adverse event
compared to similar patients who did not receive
potassium monitoring. This evidence supports existing
consensus-based guidelines.
KEY WORDS: hyperkalemia; hyperpotassemia; angiotensin-converting
enzyme inhibitor; ACEi; angiotensin receptor blocker; ARB;
spironolactone; RAAS inhibitor.
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BACKGROUND AND OBJECTIVES
Renin-angiotensin-aldosterone system (RAAS) inhibitors, in-
cluding angiotensin-converting enzyme inhibitors (ACEi), an-
giotensin receptor blockers (ARB) and aldosterone receptor
antagonists such as spironolactone, are used to treat hyper-
tension and heart failure, to decrease cardiovascular morbidity
and death after myocardial infarction, and to slow renal
disease progression in patients with type 2 diabetes and
hypertension.1–15 Although the mechanisms of action differ,
these drugs are all associated with hyperkalemia.16–21 Patients
with diabetes and renal insufficiency are considered to be at
greatest risk of hyperkalemia.17,20–25
Widespread agreement exists that serum potassium moni-
toring is a component of good clinical care for patients
prescribed RAAS inhibitors. However, available monitoring
guidelines are based on opinion, provide varying suggested
monitoring frequencies and timing, and are not tailored to
patient-specific risks.13,15–18,24,26–30 Importantly, there is a
paucity of evidence demonstrating that patients who receive
potassium monitoring have a lower risk of hyperkalemia than
patients who are not monitored.
The aim of this study was to evaluate the association
between receipt of serum potassium monitoring and occur-
rence of serious hyperkalemia-associated adverse outcomes
among ambulatory patients with diabetes newly initiating
ACEi, ARB and/or spironolactone therapy. We hypothesized
that there would be a decreased risk of hyperkalemia-associ-
ated adverse outcomes in patients with diabetes who were new
users of ACEi, ARB and/or spironolactone who received serum
potassium monitoring compared to similar patients who did
not receive monitoring. We also hypothesized that this associ-
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ation would be stronger in subsets of patients with selected
risk factors such as heart failure or chronic kidney disease.
METHODS
Study Design, Setting, and Participants
This retrospective observational study was conducted at three
integrated health care delivery systems, including Kaiser Perma-
nente Colorado (Denver, CO), Kaiser Permanente Northwest
(Portland, OR) and Kaiser PermanenteGeorgia (Atlanta, GA), with
a 2007 combinedmembership of over 1,200,000 individuals. The
Institutional Review Boards of each participating site approved
this study and waived the requirement for informed consent.
The study population included individuals with at least
12 months of continuous health plan membership and phar-
macy benefits between January 1, 2001 and December 31, 2006
(Fig. 1). The study cohort was limited to patients 18 years old
and older who had diabetes prior to initiating an ACEi, ARB or
spironolactone, defined as at least two International Classifica-
tion of Diseases, Ninth Revision, Clinical Modification (ICD9-CM)
diagnosis codes (250.##) at least 30 days apart, or one ICD9-CM
code plus at least one dispensing of a medication for diabetes.
We excluded patients with pre-existing end-stage renal disease
(ESRD) receiving chronic hemodialysis because their potassium
status is subject to frequent fluctuation and different monitoring
standards.
RAAS Inhibitor Dispensing
The study cohort was limited to new users of ACEi, ARB and/or
spironolactone, defined as having no dispensing of an ACEi, ARB
and/or spironolactone within the 180 days prior to the first
dispensing during the study period. The duration of RAAS
therapy was determined by the number and timing of prescrip-
tions. New users were defined as having continuing RAAS
inhibitor therapy if any gap between the end of one dispensings
days’ supply and the date of the next dispensing was less than
30 days. The study follow-up period continued for each member
of the study cohort until drug discontinuation (or maximum of
365 days) or censoring event (see below). For each dispensing,
information obtained included patient identifier, NDC, dispens-
ing date, strength and days’ supply. We also obtained this
information for medications considered to be potential confoun-
ders. To ensure evaluation of hyperkalemia-associated adverse
outcomes resulting in drug discontinuation, we ascertained
outcomes for 30 days after the end date of the last dispensed
days’ supply. Patients who switched drugs within a class were
followed in their original patient-drug therapy group (i.e., initial
therapy). Patientswho switcheddrug classes or had a drug added
from a new class were considered in the new patient-drug group
beginning with the date the new drug was prescribed or added
(i.e., consecutive therapy).
Assessment of Potassium Monitoring
and Hyperkalemia Outcomes
Serum potassium monitoring was defined as electronic docu-
mentation of a potassium test using each site’s laboratory test
code(s) (e.g., CPT codes and site-specific codes) and laboratory
test result values within the timeframe of RAAS inhibitor
therapy. The date of the laboratory test code(s) was considered
the monitoring date(s). The location of the laboratory test (e.g.,
ambulatory, inpatient) was determined.
Hyperkalemia risk assessment is complicated by lack of
consistent definitions of hyperkalemia across published
studies.4,7,8,19,31 Therefore, we used a consistent, stringent
definition of a serious hyperkalemia-associated adverse out-
come associated with ACEi, ARB and/or spironolactone therapy
to assess the primary outcome. This definition included an
elevated serum potassium concentration of ≥6 mmol/l and/or
a coded diagnosis of hyperkalemia (ICD9 code 276.7) that
occurred in conjunction with an emergency department (ED)
visit, an inpatient hospitalization (IP) or death attributed to
hyperkalemia (coded ICD10 code E87.5). A hyperkalemia-
associated outcome could not be identified on the basis of an
elevated potassium concentration alone; all hyperkalemia cases
required at least an IP or ED visit in conjunctionwith the elevated
potassium and/or coded diagnosis. If one patient had more than
one serious hyperkalemia-associated adverse event, only the first
adverse event was included. To ensure complete capture of
deaths, we determinedmortality frommultiple sources including
disenrollment records and hospital discharge status (at all
participating sites), and death certificates (at one site).
Potential Risk Factors and Confounders
Because diagnostic coding practices for chronic kidney disease
(CKD) underestimate patients with estimated glomerular fil-
tration rates (eGFR) ≤60 ml/min/1.73 m2,32–35 we determined
moderate to severe (stages 3 and 4)36 CKD from coded
diagnoses (ICD9 codes 585, 585.3, 585.4, 585.9, 586 or
593.9) or from: at least two eGFR ≤59 ml/min/1.73 m2,
estimated from the Modification of Diet in Renal Disease
(MDRD) equation and measured more than 90 days apart; at
least two creatinine clearance rates ≤59 ml/min estimated
from the Cockcroft-Gault equation and measured more than
90 days apart or≥2 serum creatinine concentrations >1.5mg/dl
andmeasuredmore than 90 days apart.36–38We conducted sub-
analyses in which we stratified patients by the presence or
absence of CKD.
Other variables measured as potential confounders included
age, gender, the presence of chronic diseases (using the chronic
disease score method of Clark et al.39), the presence of heart
failure (ICD9 codes 428.#, 402.01, 402.11, 402.91), diagnosis of
hypertension, provider identifier and dispensings of concomitant
medications that can affect potassium (triamterene, amiloride,
digoxin, potassium supplements, nonsteroidal anti-inflammatory
agents, trimethoprim, beta-blockers, thiazide diuretics and loop
diuretics). Further, we assessed whether potassium monitor-
ing had occurred within the 30 days before initiating RAAS
inhibitor therapy and whether a diagnosis of hyperkalemia
had occurred within the 180 days prior to starting RAAS
inhibitor therapy.
Data Sources, Data Management and Statistical
Analysis
All study data were derived from existing automated data-
bases. Using methods we have successfully applied previous-
ly,40–42 the programmer at the lead site developed and tested
SAS programs, workplans and data dictionaries to develop the
study dataset. All data checks and analyses were performed
with SAS version 9.1 (SAS Institute Inc., Cary, NC).
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We compared characteristics of patients with and without
potassium monitoring using chi-square, Fisher's exact or
Wilcoxon rank sum tests. Crude incidence rates of hyperkale-
mia-associated adverse outcomes were calculated using per-
son time (as person-years, p-y) for each patient measured as
time from drug initiation to first adverse outcome, drug
discontinuation, health plan disenrollment, ESRD diagnosis,
kidney transplant, death or end of study follow-up (365 days),
whichever occurred sooner. Unadjusted relative risks (RR) of
outcomes between monitored and not monitored patients were
calculated assuming a Poisson distribution for the total
number of outcomes for each treatment group and accounting
for person time for the study cohort overall and stratified by
age, gender, RAAS inhibitor drug group, CKD and heart
failure.
Because patients with and without potassium monitoring
are likely to differ in characteristics that can be related to
potassium monitoring and hyperkalemia outcomes, we used
propensity scores to estimate potassium monitoring (i.e.,
exposure) effects.43 The propensity scores helped to ensure
1. All members at any time between 01/01/2001 and 12/31/2006 
(n = 2,448,211) 
2b. Limit to members with > 365 days of continuous health plan membership AND pharmacy 
benefits, disregarding membership gaps of < 60 days (n = 83,197) 
4a. Limit to members > 18 years old on date of first dispensing of ACE, ARB, and/or 
spironolactone dispensing (n =28,044) 
3b. Limit to new users of ACEi, ARB, and/or spironolactone, defined as having membership > 
180 days prior to first dispensing of ACEi, ARB, and/or ARA and having no dispensing of an 
ACEi, ARB, and/or spironolactone in the 180 days prior to the first dispensing of the ACEi, 
ARB, and/or spironolactone and having continuing health plan membership and pharmacy 
benefits for at least 1 day after first dispensing (n = 28,085) 
4b. Exclude patients with end-stage renal disease (ESRD) receiving chronic dialysis. ESRD 






2a. Members with (a) a diabetes diagnosis (> 2 ICD9 diagnosis codes [all 250. 250.X, and 
250.XX codes] at least 30 days) apart OR (b) one ICD9 code (250) plus > 1 dispensing of a 
diabetes medication. Qualifying date can occur on or after 1/1/2000 and is the date of second 
diabetes diagnosis code or the latter date of the diabetes diagnosis code plus drug dispensing 
if the patient qualifies based on “b.” (n = 108,658) 










3a. Limit to patients with > 1 dispensing of ACEi, ARB and/or spironolactone. The medication 
dispensing date must occur on or after qualifying diabetes date and on or after 1/1/2001 












5. Exclude if < 1 day drug 
exposure or missing 
demographic information
5. Exclude patients with < 1 day of drug exposure or missing demographic data 
New User Cohort  
(n = 27,355) 
n = 6
Figure 1. Selection of study patients.
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that any difference in hyperkalemia outcomes between
patients with and without monitoring were not attributable to
the difference in the measured confounders. We generated a
propensity score for each patient in a logistic regression model
and then used the inverse probability propensity scores as
weights to determine the adjusted RR for outcome with the
same assumptions as those in calculations of the unadjusted
RR.44–47 Variables included in the propensity scores were
study site, RAAS inhibitor drug group, gender, age, kidney
transplant, IP and/or ED within 6 months prior to study entry,
heart failure diagnosis, CKD, hypertension diagnosis, diagno-
sis of hyperkalemia within 180 days prior to starting ACEi/
ARB/spironolactone, whether or not a potassium concentra-
tion was measured within 30 days prior to initiating ACEi/
ARB/spironolactone, chronic disease score, provider and
concomitant therapy with digoxin, a diuretic, a beta-blocker
or a potassium supplement. In calculations of adjusted RR for
outcome, the propensity score functioned as a summary of
potential confounders, along with potassium monitoring as the
exposure to estimate the association of hyperkalemia-associ-
ated adverse outcome and receipt of monitoring.
Role of the Funding Source
This work was supported by the National Institute of Diabetes
and Digestive and Kidney Diseases (NIDDK) grant no.
R21DK075076. NIDDK did not have any role in the study
design, conduct or reporting.
RESULTS
We identified 27,355 individuals with diabetes who were new
users of ACEi, ARB or spironolactone (Fig. 1), including 2,176
who also had stage 3 or 4 CKD (Table 1). Most (n=25,240,
92.3%) of these individuals were initially dispensed an ACEi
(Table 1). Seventy-one percent (n=19,391) had at least one
serum potassium concentration measured during their ACEi,
ARB or spironolactone therapy (Table 1). Individuals with and
without monitoring were different in measured demographic
and clinical characteristics (Table 1). For individuals with
potassium monitoring, the median (5th, 95th percentile) time
between RAAS inhibitor initiation and first monitoring was 15
(0, 252) days.
A serious hyperkalemia-associated adverse outcome occurred
in 184 (0.7%) individuals, with an overall population incidence
rate of 10.2/1,000 p-y (Table 2). The incidence rate of hyperka-
lemia-associated outcomes did not differ between individuals
prescribed an ACEi or ARB (p=0.36), and therefore the ACEi and
ARB groups were considered together for other analyses. Howev-
er, the incidence rate of hyperkalemia among patients prescribed
spironolactone was 96.0/1,000 p-y, whereas among patients
prescribed anACEi or ARB, the incidence ratewas 8.8/1,000 p-y.
Individuals who received potassium monitoring were 50 percent
less likely to experience a hyperkalemia-associated adverse
outcome [adjusted RR 0.50 (95% CI 0.37, 0.66)] than individuals
who did not receivemonitoring (Table 2). When stratified by those
prescribed spironolactone and those prescribed an ACEi or ARB,
potassiummonitoring remained protective against hyperkalemia
in both groups (Table 2).
Across the entire study cohort, hyperkalemia outcomes
occurred far more often among patients who also had CKD
(overall incidence rate 66.8/1000 p-y compared to 5.0/1,000 p-
y among those without CKD). Among all patients with CKD, the
adjusted RR of a hyperkalemia-associated adverse outcome for
those who were monitored compared to those who were not was
0.29 (0.18, 0.46), while among all patients without CKD, the
adjusted RR of a hyperkalemia-associated adverse outcome for
those who were monitored compared to those who were not was
0.99 (0.58, 1.71; data not shown in table).
When stratified into ACEi, ARB alone/in combination and
spironolactone subcohorts, monitoring was protective among
patients with CKD (Table 2). However, for patients with heart
failure, monitoring was not protective (Table 2). Among patients
without either CKD or heart failure dispensed an ACEi or ARB
alone or in combination, monitoring was of questionable value
(Table 2).
Potassium monitoring was protective against hyperkalemia-
associated outcomes across all age groups except patients less
than 50 years of age [<50 years: adjusted RR 4.07 (0.72, 23.19);
50–59 years: adjusted RR 0.48 (0.25, 0.93); 60–69 years:
adjusted RR 0.56 (0.29, 1.09); ≥70 years: adjusted RR 0.49
(0.30, 0.82; data not shown).
DISCUSSION
Our results demonstrate that patients with diabetes who
received serum potassium monitoring during their first year
of therapy with an ACEi, ARB or spironolactone were less likely
to experience a hyperkalemia-associated adverse event than
patients who did not receive monitoring. This protective effect
of monitoring was primarily evident in patients who also had
CKD stage 3 or 4. To our knowledge, this study is the first to
provide evidence that supports the consensus-based guide-
lines followed by clinicians who routinely monitor serum
potassium in an effort to avoid hyperkalemia-associated
adverse events among patients prescribed an ACEi, ARB or
spironolactone.
Patients with diabetes are at risk of developing hyperkale-
mia because of impaired kidney potassium excretion related to
hyporeninemic hypoaldosteronism,19,48–50 impaired renal tu-
bular function,17 insulin deficiency that limits the ability of the
body to shift potassium into cells17 and concomitant medica-
tions (e.g., potassium-sparing diuretics).51–53 In patients who
also have CKD, the risk of hyperkalemia is likely further
increased because of decreased urinary potassium excretion
associated with impaired GFR and declines in aldosterone
levels.54
The existence of a relationship among hyperkalemia, RAAS
inhibitor therapy and CKD is well established.19,31,54,55 De
Denus and colleagues suggested that, among patients with
heart failure receiving an ACEi, each mg/dl increase in serum
creatinine nearly doubled the risk of hyperkalemia in patients
with CKD.31 Further, Maddirala et al. documented that,
among patients receiving an ACEi, the incidence of hyperka-
lemia was nearly 3- and 13-fold higher among patients with
stage 3 and 4 CKD, respectively, than among patients with
stage 1 or 2 CKD.54 While our study was not designed to
determine factors associated with the development of hyper-
kalemia, our results are consistent with the findings of these
previous studies, and our results underscore the importance
of evaluating renal function and serum potassium in patients
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Table 1. Characteristics of Patients in the Study Cohort a
Characteristic All patients
(N=27,355)







Mean age in years (SD) 59.0 (13.3) 60.4 (13.0) 55.5 (13.2) <0.001
Gender: number female (%) 13,258 (48.5) 9,544 (49.2) 3,714 (46.6) <0.001
Number of patients in each initial
patient-drug group (%) c
<0.001
ACEi 25,240 (92.3) 17,825 (91.9) 7,415 (93.1)
ARB 1,538 (5.6) 1,099 (5.7) 439 (5.5)
Spironolactone 456 (1.7) 361 (1.9) 95 (1.2)
ACEi + spironolactone 95 (0.3) 85 (0.4) 10 (0.1)
ACEi + ARB 16 (0.1) 13 (<0.1) 3 (<0.1)
ARB + spironolactone 10 (<0.1) 8 (<0.1) 2 (<0.1)
Duration of initial drug
therapy (days)
<0.001
Mean (SD) 209 (143) 238 (139) 138 (128)
Median (5th, 95th percentile) 194 (30, 365) 321 (30, 365) 70 (30, 365)
Duration of consecutive drug
therapy (days)
<0.001
Mean (SD) 225 (143) 259 (134) 143 (130)
Median (5th, 95th percentile) 264 (30, 365) 365 (30, 365) 79 (30, 365)
Number of chronic diseases within
6 months prior to study entry
<0.001
Mean (SD) 6.3 (2.3) 6.5 (2.3) 5.9 (2.1)
Median (5th, 95th percentile) 6 (3, 10) 6 (3, 11) 6 (3, 9)
Hospitalization(s) and/or
emergency department visits, any
within 6 months prior to study
entry (%)
6,067 (22.2) 4,549 (23.5) 1,518 (19.1) <0.001
Outpatient visits within
6 months prior to study entry
<0.001
Mean (SD) 4.6 (4.7) 4.8 (4.9) 4.2 (4.2)
Median (5th, 95th percentile) 3 (0, 14) 3 (0, 14) 3 (0, 13)
Heart failure diagnosis (%) d 2,009 (7.3) 1,727 (8.9) 282 (3.5) <0.001
Hypertension diagnosis (%) d 18,709 (68.4) 14,135 (72.9) 4,574 (57.4) <0.001
Chronic kidney disease (CKD, %) d, e 2,176 (8.0) 1,937 (10.0) 239 (3.0) <0.001
CKD diagnosis code (%) 1,812 (6.6) 1,601 (8.3) 211 (2.7) <0.001
CKD by creatinine clearance
or glomerular filtration rate
estimate (%)
364 (1.3) 336 (1.7) 28 (0.4)
End-stage renal disease diagnosis
during study period (%)
163 (0.6) 132 (0.7) 31 (0.4) 0.004
Kidney transplant (%) d
Prior to study period 56 (0.2) 54 (0.3) 2 (0.1) <0.001
During study period 3 (<0.1) 3 (<0.1) 0
Deaths during study period (%) 259 (1.0) 207 (1.1) 52(0.7) <0.001
Concomitant therapy f
Digoxin 973 (3.6) 847 (4.4) 126 (1.6) <0.001
Diuretic 8,788 (32.1) 7,200 (37.1) 1,588 (20.0) <0.001
Potassium supplement 3,072 (11.2) 2,695 (13.9) 377 (4.7) <0.001
Digoxin and potassium supplement 411 (1.5) 377 (1.9) 34 (0.4) <0.001
Digoxin and diuretic 688 (2.5) 619 (3.2) 69 (0.9) <0.001
Diuretic and potassium supplement 2,821 (10.3) 2,481 (12.8) 340 (4.3) <0.001
Nonsteroidal anti-inflammatory agents 5,323 (19.5) 4,076 (21.0) 1,247 (15.7) <0.001
Trimethoprim 694 (2.5) 572 (2.9) 122 (1.5) <0.001
Beta-blocker 8,223 (30.1) 6,668 (34.4) 1,555 (19.5) <0.001
Patients with potassium level
measured within 30 days prior
to initiating ACEi/ARB/spironolactone
therapy
244 (0.9) 170 (0.9) 74 (0.9) 0.68
Patients with potassium level
≥6.0 mmol/l within 180 days
prior to study period
23 (0.1) 20 (0.1) 3 (<0.1) 0.09
Patients with a diagnosis of
hyperkalemia within 180 days
prior to starting ACEi/ARB/
spironolactone therapy
140 (0.5) 110 (0.6) 30 (0.4) 0.05
aPatients with diabetes who were new users of a RAAS inhibitor [i.e., angiotensin-converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB)
or spironolactone], with one or more dispensings during the study timeframe
bChi square, Fisher’s exact or Wilcoxon rank sum tests
cFor analysis, the ACEi, ARB and ACEi + ARB groups were considered together, and the spironolactone, ACEi + spironolactone and ARB + spironolactone
patient-drug groups were considered together
dDiagnosis codes were determined from up to 180 days prior to the study period through the end of the study period
eMany of the 1,812 patients in the “diagnosis code” grouping also had creatinine clearance or GFR estimates during the study period that reflected CKD
stage 3 or 4. The 364 patients in the “creatinine clearance or GFR estimate” grouping had CKD stage 3 or 4 based on at least two creatinine clearance or
GFR estimates ≥90 days apart during their study period, but did not have any diagnosis code for CKD during the study timeframe
fNot mutually exclusive, that is, a patient prescribed digoxin could have also been prescribed a diuretic, etc. Diuretic concomitant therapy does not include
patients receiving spironolactone
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in whom RAAS inhibitor therapy is initiated.31,54 In our study,
29 percent of patients with diabetes initiating RAAS inhibitor
therapy did not have serum potassium monitoring. Our finding
is consistent with the 28 to 39 percent of patients without
monitoring documented in previous investigations.40–42,56
Because of the perceived hyperkalemia risk, the National
Committee on Quality Assurance (NCQA) includes monitoring
creatinine and potassium for patients prescribed ACEi, ARB
and diuretics as a Health Plan Employer Data and Information
Set (HEDIS®) measure for performance quality.57 While our
study addressed only the subpopulation of patients with
diabetes, our results call into question whether routine
potassium monitoring is either beneficial or cost effective in
the broad population included in the HEDIS® measure.
Targeting monitoring toward those with selected comorbidities
may be more efficient.
Our study has several strengths. The study population
included a large number of new users of RAAS inhibitors.
We applied a rigorous, standardized definition of hyperkale-
mia outcome. In addition, we used propensity scores to
balance anticipated differences in measured confounders
between patients with and without monitoring. The impor-
tance of adjusting for confounding was highlighted by the
change from the unadjusted RR [1.29, 95% CI (0.87, 1.90)]
to the adjusted RR [0. 50, 95% CI (0.37, 0.66)]; if differences
in confounders between groups had not been considered,
results could have been erroneously interpreted. Finally, to
ensure correct classification of patients with CKD, we
Table 2. Relative Risks of Serious Hyperkalemia-Associated Adverse Outcomes among Patients with Diabetes Who Are New Users of ACEi,
ARB and/or Spironolactone Therapy
Serious Hyperkalemia outcome
(serum potassium ≥6.0 mmol/l
or ICD9 code 276.7 plus an
emergency department
visit or hospitalization)







































ACEi or ARB alone or in
combination (n=26,794)










Subcohorts of patients without chronic kidney diseasec or heart failure diagnosis
No chronic kidney disease
and no heart failure, ACEi
or ARB alone or in
combination (n=23,539)




No chronic kidney disease
and no heart failure,
spironolactone (n=266)




Subcohorts of patients with chronic kidney diseasec
Chronic kidney disease stage
3 or 4; ACEi or ARB
alone or in combination
(n=1,482)





stage 3 or 4, spironolactone
(n=42)
4 179.0 4 187.5 0 0 – –
Subcohorts of patients with heart failure diagnosis
Heart failure, ACEi or ARB
alone or in combination
(n=1,232)










Subcohorts of patients with chronic kidney diseasec and heart failure diagnosis
Chronic Kidney disease stage
3 or 4 and heart failure,
ACEi or ARB alone or in
combination (n=541)





stage 3 or 4 and heart
failure, spironolactone (n=112)




aComparing patients with monitoring to patients without monitoring based on Poisson regression accounting for person time
bComparing patients with monitoring to patients without monitoring based on Poisson regression accounting for person time and weighting with the
inverse of propensity scores. For variables included in the propensity score models, please see the Methods section
cChronic kidney disease was determined from any of the following: an ICD9 code indicating chronic kidney disease, at least two eGFR ≤59 ml/min/
1.73 m2, estimated from the Modification of Diet in Renal Disease (MDRD) equation and measured at least 91 days apart, at least two creatinine clearance
rates ≤59 ml/min estimated from the Cockcroft-Gault equation and measured at least 91 days apart, or at least two serum creatinine concentrations
>1.5 mg/dl
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evaluated not only diagnosis codes, but also laboratory
values to identify patients with estimated glomerular filtra-
tion rates and creatinine clearance values consistent with
stage 3 and 4 CKD. This resulted in classifying an additional
364 (17%) patients as having CKD.
As with all observational studies, this study is subject to
misclassification biases. Misclassification of outcomes could
have occurred if hyperkalemia was not coded as a diagnosis.
Additionally, we likely did not identify hyperkalemia-associated
deaths in the community because hyperkalemia-associated
arrhythmias resulting in death are unlikely to be listed on the
death certificate. Misclassification of risk factors could have
occurred if we did not identify all patients with CKD or heart
failure or had incomplete disease severity information.33 Finally,
while propensity scores assist in reducing bias associated with
measured confounders, their use cannot reduce bias associated
with unmeasured confounding.
Study data did not permit evaluation of whether the pre-
scribing physician ordered a laboratory test that the patient did
not complete. Thus, we could not differentiate between patient
and physician factors that contributed to lack of monitoring. We
also did not have blood glucose information available for study
patients and therefore could not include severe hyperglycemia
(i.e., contributing to intravascular potassium shifts) in the
potential confounders.
Because this study was conducted within integrated health-
care systems, the results may not be generalizable to other
settings. Yet, patients with diabetes or those prescribed RAAS
inhibitors are unlikely to have differing characteristics simply
because of the delivery system in which they enroll. Further,
because we compared risks between monitored and non-
monitored groups, these results should be applicable to patients
in other health care settings.
The results of this work provide guidance in developing a
framework for evidence-based potassium-monitoring recom-
mendations for patients with diabetes prescribed RAAS inhibi-
tors. Because randomized trials of monitoring practices are
unlikely to be undertaken, such guidelines will of necessity be
based on analysis of existing data. It will be important in future
studies to determine more precisely the patient groups that
benefit most from monitoring, such as whether monitoring is
beneficial for patients without diabetes who have CKD. It will
also be important to study whether interventions intended to
improve potassium monitoring are effective, and to evaluate the
cost effectiveness of both monitoring and of interventions.
We conclude that patients newly prescribed ACEi, ARB and
spironolactone who have both diabetes and CKD and receive
serum potassium monitoring are much less likely to experience
a serious hyperkalemia-associated adverse event than similar
patients without monitoring. This study offers tangible evidence
to support published guidelines that recommend monitoring
serum potassium among patients with these clinical character-
istics who are started on RAAS inhibitors.
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